ERT, Inofab join forces on decentralized respiratory trials

By Jenni Spinner

- Last updated on GMT

(Milena Shehovtsova/iStock via Getty Images Plus)
(Milena Shehovtsova/iStock via Getty Images Plus)

Related tags Ert Clinical trials COVID-19 Coronavirus Decentralized trials

The two companies will work together to promote technology for at-home clinical research conducted in trials focused on developing respiratory therapies.

Clinical endpoints data specialists ERT is joining forces with Inofab Health, a heathcare technology company focused on designing and developing ultrasonic spirometry technology. The partnership is intended to expand ERT’s portfolio of technology solutions for decentralized trials, providing sponsors and contract research organizations (CROs) a range of options for continuing their research during the pandemic, and beyond.

In the face of COVID-19, sponsors are on the hunt for reliable collection methods that make it possible to keep clinical trials going without compromising the safety of clinical trial patients or calling upon them to travel to investigative site appointments. Virtual and decentralized trial solutions like those facilitated by ERT enable at-home capture of high-quality data, right in the patients’ homes.

According to Achim Schülke, executive vice president of respiratory solutions at ERT, Inofab’s technology is a good complement to ERT’s offerings.

We chose to partner with Inofab based on their proven capabilities in meeting respiratory patients’ healthcare needs and their award-winning ultrasonic spirometer, Spirohome​,” Schülke said. “This partnership enables ERT to further drive innovation in trial virtualization and supports our commitment to offering the best range of trial continuity options, specifically for sponsors developing new respiratory disease treatments​.”

Patients diagnosed with lung disease face a higher risk of developing serious complications from COVID-19, meaning many are apt to steer clear or clinics, investigative sites and other places requiring travel away from home. The goal of the ERT and Inofab collaboration is to come up with patient-friendly, easy-to-use solutions enabling at-home, patient-administered testing, promoting patient comfort and safety while simultaneously ensuring high-quality data collection to keep respiratory trials on track.

Inofab chief technology officer and co-founder Kerem Yasar said partnering with ERT made sense for the company due to its connection with sponsors.

Spirohome plays a critical role for endpoint data collection and we’re excited to work with ERT in delivering virtual trial solutions that help clinical trial sponsors continue developing new treatments for the millions of patients living with respiratory disease​” Yasar said.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more